Collectively, RDV may relieve LPS-induced AKI by inhibiting NF-κB and MAPK signaling, which will decrease the expression of NLRP3 and inflammatory cytokine release (Figure 6). This evidence concerns the gene NLRP3 and acute kidney injury.